A powerful drug combo eliminates 20 percent of tumors among advanced melanoma patients and increases the two-year survival rates. The combination of ipilimumab and nivolumab can be beneficial but further study is needed to address the side effects.
A powerful drug combo eliminates 20 percent of tumors among advanced melanoma patients and increases the two-year survival rates. The combination of ipilimumab and nivolumab can be beneficial but further study is needed to address the side effects.
Share this Article
Recommended